By Fineline Cube 
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official market launch of its combination antibacterial Recarbrio (imipenem, cilastatin, and relebactam) in China. Recarbrio is indicated for patients aged 18 and older for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), caused by susceptible gram-negative microorganisms. It is also approved for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI), caused by susceptible Gram-negative microorganisms where limited or no alternative treatment options exist.
Production and Distribution
The first batch of Recarbrio, which received initial marketing approval in China in November last year, has been packaged at MSD’s Hangzhou plant. This local production underscores MSD’s commitment to efficiently serving the Chinese market.-Fineline Info & Tech